0001493152-23-005752.txt : 20230222 0001493152-23-005752.hdr.sgml : 20230222 20230222092028 ACCESSION NUMBER: 0001493152-23-005752 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230222 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230222 DATE AS OF CHANGE: 20230222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sanara MedTech Inc. CENTRAL INDEX KEY: 0000714256 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 592220004 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39678 FILM NUMBER: 23650753 BUSINESS ADDRESS: STREET 1: 1200 SUMMIT AVE STREET 2: SUITE 414 CITY: FORT WORTH STATE: TX ZIP: 76102 BUSINESS PHONE: 817-529-2300 MAIL ADDRESS: STREET 1: 1200 SUMMIT AVE STREET 2: SUITE 414 CITY: FORT WORTH STATE: TX ZIP: 76102 FORMER COMPANY: FORMER CONFORMED NAME: WOUND MANAGEMENT TECHNOLOGIES, INC. DATE OF NAME CHANGE: 20080611 FORMER COMPANY: FORMER CONFORMED NAME: MB SOFTWARE CORP DATE OF NAME CHANGE: 19960805 FORMER COMPANY: FORMER CONFORMED NAME: INAV TRAVEL CORPORATION DATE OF NAME CHANGE: 19920703 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 22, 2023

SANARA MEDTECH INC.

(Exact name of registrant as specified in its charter)

Texas		001-39678		59-2219994
(State or other jurisdiction of		(Commission		(IRS Employer
incorporation)		File Number)		Identification No.)

1200 Summit Avenue, Suite 414

Fort Worth, Texas

76102

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (817) 529-2300

(Former name or former address, if changed since last report)

Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		SMTI		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02

Results of Operations and Financial Condition.

On February 22, 2023, Sanara MedTech Inc. (the “Company”) issued a press release announcing certain unaudited preliminary financial results for the fourth quarter and full year 2022. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release issued February 22, 2023 (furnished pursuant to Item 2.02).
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	February 22, 2023

		Sanara MedTech Inc.

		By:	/s/ Michael D. McNeil
		Name:	Michael D. McNeil
		Title:	Chief Financial Officer

EX-99.1 2 ex99-1.htm

Exhibit 99.1

Sanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2022

FORT WORTH, TX / GLOBENEWSWIRE / February 22, 2023 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin care markets, announced today certain unaudited preliminary results for the fourth quarter and full-year 2022.

Selected Fourth Quarter and Full-Year 2022 Preliminary Results (Unaudited)

	●	Net revenue of approximately $15.3 million for the three months ended December 31, 2022, compared to net revenue of $7.0 million for the three months ended December 31, 2021, which would result in a record net revenue quarter and represent a 119% increase from the prior year period.

	●	Net revenue of approximately $45.8 million for the year ended December 31, 2022, compared to net revenue of $24.1 million for the year ended December 31, 2021, representing a 90% increase from the prior year. The higher net revenues in 2022 were primarily due to increased sales of surgical products as a result of our increased market penetration and expanded product offering, our continuing strategy implementation of expanding our sales force and independent distribution network in both new and existing U.S. markets, as well as additional revenues from the Scendia Biologics, LLC (“Scendia”) acquisition.

	●	Operating loss is expected to be between $2.0 million and $3.5 million for the three months ended December 31, 2022, compared to an operating loss of $3.4 million for the three months ended December 31, 2021.

	●	Operating loss is expected to be between $11.0 million and $12.5 million for the year ended December 31, 2022, compared to operating loss of $7.4 million for the year ended December 31, 2021. The higher operating loss in 2022 was primarily due to higher expenses related to research and development, higher non-cash amortization expense related to intangible assets acquired as part of our acquisitions of Precision Healing Inc. and Scendia and higher costs related to sales force expansion and operational support.

	●	Cash and cash equivalents were approximately $9.0 million as of December 31, 2022.

	●	As a result of the dissolution of Sanara Pulsar, LLC (“Sanara Pulsar”), an entity that was majority-owned by a wholly owned subsidiary of Sanara, we recorded a non-cash loss on disposal of investment in the fourth quarter of 2022 totaling approximately $1.0 million. The loss on disposal of investment will be included in “Other expense” in Sanara’s Statement of Operations for the year ended December 31, 2022. At the time of the formation of Sanara Pulsar, Sanara Pulsar and Wound Care Solutions, Limited (“WCS”) entered into a supply agreement whereby Sanara Pulsar became the exclusive distributor in the United States of certain wound care products, including the Sanara Pulsar II AWI Wound Debridement System, that utilized intellectual property developed and owned by WCS (collectively, the “Pulsar Products”). When we formed Sanara Pulsar, we believed the Pulsar Products would provide clinicians with a novel debridement solution. We also believed the Pulsar Products would receive an expanded reimbursement code for use by all clinician types. Ultimately, we did not receive an additional reimbursement code, which limited the adoption of the Pulsar Products.

Zach Fleming, Sanara’s CEO, stated, “In 2022, Sanara saw significant net revenue growth as a result of increased sales of our surgical products including those we market through our acquisition of Scendia and the products we license from Cook Biotech Inc. The efficacy of our CellerateRX^® Surgical line of products and our ability to offer an expanded portfolio of products were both key drivers of our success in 2022 and we believe they will continue to help drive growth in 2023.”

Our independent registered public accounting firm has not completed its procedures with respect to the preliminary financial information or its audit of our financial statements for the year ended December 31, 2022. Our actual results may differ from these estimates as a result of the completion of our audit and other developments that may arise between now and the time our financial results for the fourth quarter and year are finalized.

About Sanara MedTech Inc.

With a focus on improving patient outcomes through evidence-based healing solutions, Sanara MedTech Inc. markets, distributes and develops surgical, wound and skincare products for use by physicians and clinicians in hospitals, clinics and all post-acute care settings and offers wound care and dermatology virtual consultation services via telemedicine. Sanara’s products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara markets and distributes CellerateRX^® Surgical Activated Collagen^®, FORTIFY TRG^® Tissue Repair Graft and FORTIFY FLOWABLE^® Extracellular Matrix as well as a portfolio of advanced biologic products focusing on AMPLIFY^™ Verified Inductive Bone Matrix, ALLOCYTE^™Advanced Cellular Bone Matrix, BiFORM^® Bioactive Moldable Matrix and TEXAGEN^® Amniotic Membrane Allograft to the surgical market. In addition, the following products are sold in the wound care market: BIAKŌS^™ Antimicrobial Skin and Wound Cleanser, BIAKŌS^™ Antimicrobial Wound Gel, BIAKŌS^™ Antimicrobial Skin and Wound Irrigation Solution and HYCOL^® Hydrolyzed Collagen. Sanara’s pipeline also contains potentially transformative product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement, and cell compatible substrates. The Company believes it has the ability to drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. Sanara is constantly seeking long-term strategic partnerships with a focus on products that improve outcomes at a lower overall cost. In addition, Sanara is actively seeking to expand within its six focus areas of wound and skin care for the acute, post-acute, and surgical markets. The focus areas are debridement, biofilm removal, hydrolyzed collagen, advanced biologics, negative pressure wound therapy products, and the oxygen delivery system segment of the wound and skincare market.

Information about Forward-Looking Statements

The statements in this press release that do not constitute historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “anticipates,” “believes,” “contemplates,” “continue,” “could,” “estimates,” “expect,” “forecasts,” “guidance,” “intend,” “may,” “plan,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among others, statements regarding the Company’s expected net revenue and operating loss for the fourth quarter and full fiscal year ended December 31, 2022, the Company’s expected cash and cash equivalents as of December 31, 2022, the Company’s noncash loss on disposal of investment during December 2022 and the Company’s business strategy. These items involve risks, contingencies and uncertainties such as the preliminary financial information remaining subject to changes and finalization based upon management’s ongoing review of results for the fourth quarter and full fiscal year 2022 and the completion of all quarter and year end closing procedures, the extent of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, uncertainties associated with the development and process for obtaining regulatory approval for new products, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements.

All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.

Investor Contact:

Callon Nichols, Director of Investor Relations

713-826-0524

CNichols@sanaramedtech.com

SOURCE: Sanara MedTech Inc.

GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W_.*9)*D4 M;22,%11EF)P *2218P6<[5 )+'H/K4IK"O;J>&>;1(KE9=5EC>YM) M9[?,$&,[0<>F/\\50N?$<)EDEE\1V^/PK54FSG= M:W]?UY=]SJ)KZ-KFP@\WRI)P9%CDB.6 '/\ ND9J^\B1J6=@JJ,DGC ]:Y,7 MUS:0VVIOJL4.D26:QP+>1GS?./W68_SJRNIO<72Z5/>F&]LD2:]E$6(9%(Y M+< &ATWT$JV]]_Z_X?H=&DBR(KHZ-K-CK^ ME0ZCILXFMI1E6 P0>X(['VJI0E'5DQG&6B-'(HR*2D_.H+'9%&13>U+0 N11 MD4WTH]* '9%&13<^M&: '9%&13?049Z4 .R**;^M*.M #)=OE/O3]7+Z&012B#4C;RN$C1I,,J-GK MCU/2N7\07KO;:[+)<:;<6(MOLL*QR^7,]R/^6;-VR>WO6U.*;.:K-I-?U_P# MGO&/C!KIM?M+3Q,FG0V"Q(S);N763> 0&'4'ID5)#X8U#4V%]I]C9"XM+)3I M&J,-HD=@"79!QD[F/(XJOX;MKO5O$&G6=T^F6&RTQJFB/%NDF"D[7;(.2 M3D?C7KB(L:*B*%51A548 'TK2<^3W4B(4N?WFSS?6F\6I86=AJ\-C)IRZ>\F MHZELW>1, 2'5>,E?EZ#DDUC^&O$GGS:'I6J^(;;5].U.VD3RYK5A))*'X#,1 MPHX S7L#QI+&T.RL+MS)!%K,D<>JVT,DJZ?9R%P\&0 2O.?2NH M3;Y:A5V# P,8P,?I7/>'KS2SX?TR5)+:&=H5ME)D#LLFW)C#=20>WM6K803B M*!Y[]KF6-6CD9 %21L]<#H1C'6LY[NY5*R2MK3@*"/;H?PKU^N6L_%^GZKXLU'PK=V30W-L-RBXP5G7U4?B#2I MMJ^ET:5%>VH[3?'GA/7E\FVU>UD:4;?)F^1FSVPV*GL-)T3P1HE]-9H;>Q7= M?^%VU'4OASXUT M*&ZDO8+%GBLI2V=R#)P#Z$*"![U:C%KW7H0Y23]Y:E[2+7Q?\3!+K$^MS:+H MSN5MK>V&&=0>IZ?GSGGM47BYO&O@+P[?=GM),\9/=2 1GW M[=^Q^%6I6FH?#S3$M75FMD,$RKU5P>X]^M4_C)J=I9?#^ZM)G7[1>,B0QYY) M#!B<9Z #K5J3]IR6TN0XKV?-?4H^+M:U.T^"UCJ=O?SQ7[QVY:X1L.Q;&?SS M3++P_P"+?&^FP:GJ/B.YTBWFC4V]G:CYMN.&<\./^2 Z?_UQM?Z5 MZAI QHE@ ,#[-&!_WR*ERY8W7=E)(?$WC*7PEX6NA91VJAK^^'52>P/;TXZGTI^H<_M!:7 MW_XEC=^GW_\ /:J_@>>+2OBQXNTR\8)=7DOGP%OXUR6P/P8?D:K3X[:V)U^' MI MY(-=7J%Y>?"WP3H[?SI?C*#!9>'M3>-GM;+4D>?:,X'!Y_+]:MM.IR6T)2:I\]]2&P\">,=6 MMTU+6/&5[:7THWK!;CY8L] 1D#\!7+>-?$OC?P[>V6C7NI2)<0[G2^MOE6ZC M(P"RX^\"#_GFO>+6[AO;6*ZMI%D@F0.CJ!(RCJ<]__KUV1;A+".2-W?ZUE2>HZ^W]?U^1R&@QZMH6L:1J>HVEC=0W-F3?Z],?+=02=JD MG&,?*.1DUZJCI(BNC!E894KT(KSKQT^H:YXF99ZUKVGSSQ:?J-C(MU9*FCZ4/G$,BX!5FQU4!AR>35RIN>J)A5C M#1L]7ED2&-Y975(T!9F8X"@=237DOB._U#4M6U:XM3IVGH+8'3=7BDWRW"@C M>J8/)ZC@UL9M+6T$[R-%LD:XP/G"XXS70V4\PAA6?3S;2.C22*F&5&STR.I.<_G6 M?ITNHK8P6.KS&>YN]Y%S9IM1%_AR1T.*WU&%"\G'<]ZRJ/74NE'JOZ_KU#M7 M+>+/ 6E^+)(;J62>SU&$8BO+9L.!Z>XKJ3TKE-1U:[T_Q@"TC-IHBC2:/LA= MB _YXS2IJ3?NO4JO4C3BG-:-V,!_A?K=RGV>]\?:K-9GAH@I4D>F=Q_E7:^' MO#VG>&-(CTW3(=D*DEBQRSL>K,>YK*\7ZM=VZ1VNG2F.1 )YY$_@CR!C\<_I M6I=:T8KPV5I93WMQ&H:41D 1YZ D]SUQ5R4Y13[F4:U*,Y1[6_I'(ZA\*(EU MB;4_#FN7FA2SG=+' -R$^PR,=^.?;%-?X1VEUIUZNIZS>:AJER@07TXW&$!@ MV$4DXSCU[UUS>([1=,^V&.;=YOD?9]O[SS?[F/6LV^U>XGO](MIK.YL9'NU( M#D$.NT\9!^G%5'VK%.I12NM?^"&L^"8M9\"P>%WOGCBB6)//" EMGMG':NEM M8!:V<%N"6$4:IG'7 Q7+:CIU[;ZOIUM'KNHB.[DD##>/E &1CBM!-0DL';3; M:*]U:>#F61F4%<\@$G SCL*F4&TK._4<:Z4FI1M;3OY]"*?PE'/X\MO%/VMQ M)!;&W%OMRI'/.?\ @55O&'P_TSQ=)!=O+/9:E!Q%>6YPP'H?45J-XBM%TR.[ M$<[/))Y*VX3]X9.A7'J._:J]WJESIS5O\ "VXN)HAXA\5:CJ]G$P86KY1&QC ;DY%;_A+P9!X2N-4D@N3* ME_/YHC\L*(ASA1CL,X_"DMO% @TZTFETZ\^Q%$5KQ@-H. ,D=<9[XKIQSS1- MS6DMAT94IZP.;\(>$8_"4>HI'>-4L4EP=K/'*27 & ?\ 9/4<>E:JHWN<[I)-6W_K7\C#DTI; M_5IIO^$"Q"W U9[9+J\NE6VOXXY]T$07.[ / MH>U;G]GV[7%M<.C-/;(5C=G.0".<^M3>3'LD3:IC?.5P,'/7\Z'4Z(/8WU>_ M]>7JAMO$(D?;,\BNQ<;VR%'HOMQ4W^>E-C01H$4#:.% XP.P%/Q61T)60AK# MFTHWNMZ@+B$FTN+-(MQ[G+9Q^>:W:3%5&3CL1.FIVOT_K]3D7\.WEMX:OHY6 M-WJ%PR!F3J54@*,GV'_ZZ+_29;?6;FZ>SO+N"Z"L#:SE"C!0N"-PR#CK77CZ M4?2M/;2ZG.\'3LDNGS[_ .9RAT>XBT^VO+*Q:.Z@NOM+6TL^]I!C:AQ4E MW)J6K7^F,-+FM[:WN@\K3,H;H>P/0?X5TW?/-'X_K1[5[M#^JJUD[+3MT,C5 M;6XGUO1YHXBT4$CM(P_ARN!6/>Z3+;:U>7#V5Y=P73"1&M+@J4;&"&7(]!S7 M84_P"%CE!HTUK;6-_96!2X@N&GDM9)M[N&&T_,?XL8_E[U M=N+K4-4TS4(?[*FMU:V=4,KKN=R", _K6[1_GK0ZC>K0EAU&ZB[)[[=K&'J M5C<2^#C90PDS_9T41@=P!Q6W&"(U!&" *7%&*ARNK&T::B[KLE]P4M)2U)H% ' HH'6@#_V0$! end EX-101.SCH 4 smti-20230222.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 smti-20230222_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 smti-20230222_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Feb. 22, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Feb. 22, 2023
Entity File Number	001-39678
Entity Registrant Name	SANARA MEDTECH INC.
Entity Central Index Key	0000714256
Entity Tax Identification Number	59-2219994
Entity Incorporation, State or Country Code	TX
Entity Address, Address Line One	1200 Summit Avenue
Entity Address, Address Line Two	Suite 414
Entity Address, City or Town	Fort Worth
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	76102
City Area Code	(817)
Local Phone Number	529-2300
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	SMTI
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000714256 2023-02-22 2023-02-22 iso4217:USD shares iso4217:USD shares 0000714256 false 8-K 2023-02-22 SANARA MEDTECH INC. TX 001-39678 59-2219994 1200 Summit Avenue Suite 414 Fort Worth TX 76102 (817) 529-2300 false false false false Common Stock, $0.001 par value SMTI NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://sanaramedtech.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm smti-20230222.xsd smti-20230222_lab.xml smti-20230222_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "smti-20230222_lab.xml" ] }, "presentationLink": { "local": [ "smti-20230222_pre.xml" ] }, "schema": { "local": [ "smti-20230222.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "SMTI", "nsuri": "http://sanaramedtech.com/20230222", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-02-22to2023-02-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://sanaramedtech.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-02-22to2023-02-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sanaramedtech.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001493152-23-005752-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-005752-xbrl.zip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end